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Supplementary Information 1 
 2 
Table S1: Sampling locations and background information 3 




































































































Table S2: Pharmaceuticals and TPs with their quantification limits (LOQ) and analytical recoveries 6 
 7 
Pharmaceutical or transformation 











10,11-trans-diol-carbamazepine c 35079-97-1 0.01 101.5 1.6 2.9 
2-hydroxy carbamazepine c 68011-66-5 0.01 104 1.1 10 
3-hydroxy carbamazepine c 68011-67-6 0.01 92.6 2.3 4.5 
4-acetaminophen sulphate c 32113-41-0 0.025 66.2 2.4 10.9 
4-formylaminoantipyrine c 1672-58-8 0.01 111.9 1.4 3.8 
acetyl sulfadiazine d 127-74-2 0.01 93 3.5 3.4 
α-hydroxy metoprolol c 56392-16-6 0.01 109.1 3 10.4 
AMPH c 38604-70-5 0.01 92 1.7 4.4 
erythromycine A c 23893-13-2 0.05 36.8 7.1 17.1 
atenolol a 29122-68-7 0.01 96.5 2.7 4.7 
bezafibrate a 41859-67-0 0.01 90.7 1.2 2.5 
carbamazepine a 298-46-4 0.01 94.6 0.9 1.2 
carbamazepine-10,11-epoxide c 36507-30-9 0.01 108.2 1.7 6.5 
ciprofloxacin a 85721-33-1 0.50 99.1 1.7 6.1 
clenbuterol a 37148-27-9 0.01 108.4 3.9 11.4 
clindamycin 18323-44-9 0.01 76.1 2.9 9 
clofibric acid 882-09-7 0.01 80.9 3.6 10.5 
cortisol a 50-23-7 0.025 92.9 2.9 12.1 
cyclophosphamide a 50-18-0 0.01 52.8 5.8 18.8 
diatrizoate (amidotrizoic acid) a 117-96-4 0.01 96.9 1.5 2.6 
diclofenac a 15307-79-6 0.01 102 1.4 4 
dimethylaminophenazone a 58-15-1 0.01 46.2 6.5 15.7 
erytromycin A a 59319-72-1 0.025 89.9 3 5.9 
phenazone a 60-80-0 0.01 105.9 6.2 9.5 
fluoxetine a 59333-67-4 0.01 97.9 2 7 
furosemide a 54-31-9 0.01 72.7 6.3 6.9 
gemfibrozil a 25812-30-0 0.01 105.4 5.3 5.3 
guanylurea c 141-83-3 0.05 103.6 1.4 7 
hydroxy ibuprofen c 51146-55-5 0.50 99.7 1.2 4.6 
ifosfamide a 3778-73-2 0.01 110.6 2 9.7 
ketoprofen a 22071-15-4 0.01 78.8 1.4 1.9 
lincomycin a 859-18-7 0.01 134.8 2.8 4.9 
metformin a 657-24-9 0.05 96.3 2 3 
metoprolol a 37350-58-6 0.01 103.2 1.9 6.7 
metronidazole a 443-48-1 0.01 73.5 3.7 14.7 
N4-acetyl sulfamethoxazole c d 21312-10-7 0.01 104.2 2.2 4.2 
naproxen a 22204-53-1 0.01 256.7 7.7 7.7 
norfluoxetine c 83891-03-6 0.50 108.4 14 11.8 
o-desmethyl metoprolol c 62572-94-5 0.01 85.9 3.1 3.4 
o-desmethyl naproxen c 
(R) 123050-98-6 / (S) 
52079-10-4 0.05 111.4 2 
9.4 
o-Desmethyl tramadol c 73986-53-5 0.01 81.1 3.4 5.2 
oxcarbamazepine a (c) 28721-07-5 0.01 93.6 1.1 21.5 
paracetamol a 103-90-2 0.01 203 7.5 17.1 
paroxetine a 61869-08-7 0.05 65.7 5.1 4 
penicillin V a c 132-98-9 0.01 97.9 2.7 5.1 
pentoxifylline a 6493-05-6 0.01 103.6 2 3.3 
pindolol a 13523-86-9 0.01 111.1 0.8 9.2 
prednisolone a 50-24-8 0.05 89.9 3.2 4.8 
propranolol a 525-66-6 0.01 107 2.9 3.4 
propyphenazon a 479-92-5 0.01 104 1.1 5.7 
salbutamol a 18559-94-9 0.01 86.6 2.2 5 
salicylic acid c 69-72-7 < 5.0 79.2 146.4 4.6 
sotalol a 3930-20-9 0.01 105.9 2.6 7.2 
sulfachloropyridazine b 80-32-0 0.01 91.6 1.8 3 
sulfadiazine a, b 68-35-9 0.01 110.3 0.9 8.2 
sulfamethoxazole a (b) 723-46-6 0.01 98.2 1.6 7.2 
sulfaquinoxalin b 59-40-5 0.01 102.1 1.5 10.2 
terbutaline a 23031-32-5 0.01 73.2 5.5 2.1 
tramadol a 27203-92-5 0.01 115 2.2 5.9 
trimethoprim a, b 738-70-5 0.01 109 2.6 7.1 
venlafaxine a 93413-69-5 0.01 113.6 3.3 2.9 
a human pharmaceutical    b (mainly) veterinary pharmaceutical 8 
 c transformation product of human pharmaceutical d transformation product of (mainly) veterinary pharmaceutical 9 
    10 
 3 
Table S3: Consumption of pharmaceuticals in Belgium and the Netherlands obtained from RIZIV 11 
(Belgian National Institute for Health and Disability Insurance)  and SFK (Dutch Foundation for 12 





Belgian per capita annual 
consumption (g/Y) 
Dutch per capita annual 
consumption (g/Y) 
metformin HCl 16.288 12.702 c 14.454 11.272 
furosemide  0.123  0.234  
propranolol HCl 0.232 0.204 c 0.089 0.078 c 
sotalol HCl 0.295 0.260 c 0.245 0.216 c 
metoprolol tartrate / succinate 0.211 0.138 c 1.808 1.177 c 
atenolol  0.155  0.193  
bezafibrate  0.010  0.025  
metronidazole  0.014  - e  
erytromycin A stearate / ethylsuccinate 0.011 0.009 c 0.045 0.034 c 
clindamicin HCl∙H2O 0.131 0.116 c 0.066 0.059 c 
lincomycin HCl 0.006 0.006 c - e  
diclofenac Na / K 0.405 0.375 c 0.409 0.380 c 
naproxen Na a 0.661  0.800  
ketoprofen  0.014  0.007  
tramadol HCl 0.595 0.523 c 0.287 0.252 c 
paracetamol  1.143  - e  
carbamazepine  0.513  0.608  
oxcarbamazepine  0.054  - e  
venlafaxine HCl 0.385 0.340 c 0.215 0.190 c 
metronidazole  0.080  0.083  
gemfibrozil  0 d  0.305  
sulfamethoxazole Trimethoprim b  - e  0.233  
trimethoprim Sulfamethoxazole b - e  0.030  
a Mass of additive not included in the Defined Daily Dose 15 
b Cotrimoxazole is a combination of sulfamethoxazole and trimethoprim in a 5:1 mass ratio 16 
c Consumption of pharmaceuticals corrected for additions to the formulation (e.g. HCl, Na, K, tartrate, succinate, stearate or 17 
ethylsuccinate) 18 
d gemfibrozil is not prescribed in Belgium 19 
e no data obtained  20 
 4 
Description of chemical analysis 21 
 22 
Internal standards 23 
0.5 µg/L internal standard is added to the sample, subsequently, the sample is filtered over a 0.20 µm 24 
filter and directly injected.  25 
 26 
Internal standards are: 27 
  28 
Internal standards CAS nr. Elemental composition 
Atenolol-d7 1202864-50-3 C14D7H15N2O3 
Atrazine-d5 163165-75-1 C8D5H9ClN5 
Bentazone-d6 - C10D6H6N2O3S 
Benzotriazool-d4 1185072-03-0- C6D4HN3 
Carbamazepine-d10 132183-78-9 C15D10H2N2O 
Fluoxetine-d5 1173020-43-3 C17D5H13F3NO 
Gemfibrozil-d6 1184986-45-5 C15D6H16O3 
Metformin-d6 1185166-01-1 C4D6H5N5 
Paracetamol-d3 60902-28-5 C8D3H6NO2 
Phenazone-d3 65566-62-3 C11D3H9N2O 
Sulfamethoxazole-d4 1020719-86-1 C10H7D4N3O3S 
 29 
Injection and liquid chromatographic separation 30 
Two LC separations and subsequent analysis are performed. Most compounds are separated by reversed 31 
phase chromatography while metformin and guanylurea are separated by normal phase chromatography. 32 
Details are given below. 33 
 34 
Hypersil Gold - reversed phase 
Flitration of the sample Spartan 0.20 µm filter 
UHPLC-pump Accela 
Autosampler Accela 
Autosampler washing liquid 70 % acetonitrile, 15 % methanol, 15 % Milli-Q 
Analytical column Hypersil Gold 1.9 µm 100 x 2.1 mm  
Guardcolumn Krudkatcher Ultra HPLC in-line Filter 0.5 µm  
Column thermostate Accela 25
 
°C 
Vials 1.8 ml; afmetingen12 x 32 mm 
Tray temperature 15 °C 
Divert valve (heart-cutting ) 0.5 – 14 min 
 35 
ZIC HILIC - normal phase (aberrations of the previous separation are given) 
Autosampler washing liquid 70 % acetonitrile, 30 % Milli-Q 
Analytical column ZIC HILIC 3.5 µm 100A 100 x 2.1 mm 
Guardcolumn Guard column ZIC HILIC 14 x 1,0 mm, 5µm 
Injection loop volume 50 µl  
Divert valve (heart-cutting ) 3 - 9 min  
 36 
Separation gradient program UPLC - Hypersil Gold column 
Step Time (m) Milli-Q + 0.05 % acetic acid ( 
%) 





0 95 5 300 
1 1 95 5 300 
2 15 0 100 300 
3 17 0 100 300 
4 17 95 5 300 
5 20 95 5 300 
  37 
 5 
Separation gradient program UPLC – ZIC HILIC column 
Step Time (m) Milli-Q + 5 mM ammonium formate pH 3.2 ( 
%) 
Acetonitrile ( %) Flow (µl/min) 
0
 
0 5 95 300 
2 6 90 10 300 
4 8 5 95 300 
 38 
Analysis and mass spectrometric settings  39 
Mass spectrometer 
Mass spectrometer TSQ Vantage 
Scan method SRM 
Pressure colision cell (Ar) 1.5 mTorr 
LC/MS interface ESI 
Ionisation mode positive/negative 
Cycle time 0.50 s 
Spray voltage  3.0/2.5 kV 
Capillary temperature  275 °C 
Vaporizer temperature 285 °C 
Sheath gas (N2) 30 (Arb) 
Auxilliary gas (N2) 10 (Arb) 
Ion sweep gas (N2) 10 (Arb) 
Resolution Q1 0,7  (FWHM) 
Resolution Q3 0,7  (FWHM) 
 40 
 41 
All samples were analysed within one analytical run in order to reduce variability of the analytical 42 
procedure. Blanks and external standards were measured once every ~10 samples. Additionally both the 43 
blank matrix and sample matrices were spiked with the test chemicals to determine matrix dependent 44 
differences in sensitivity. The recoveries of the external standards and matrix effects did not exceed the 45 
range of 75% to 125%, so no corrections were made for the different samples. 46 
